Thaum Lub Rau Hli 10, Lub Chaw Saib Xyuas Kev Tshuaj Xyuas Tshuaj (CDE) ntawm Lub Chaw Tswj Xyuas Khoom Siv Kho Mob Hauv Tebchaws (NMPA) tau tshaj tawm tias Trastuzumab Deruxtecan (T-DXd, DS-8201a) raug pom zoo kom tau txais kev tshuaj xyuas ua ntej rau kev kho mob rau cov neeg laus uas muaj HER2-positive gastric lossis gastroesophageal junction (GEJ) adenocarcinoma uas tau txais ib qho kev kho mob ua ntej.
Hauv qhov kev sim theem ob DESTINY-Gastric01, DS-8201 tau txhim kho cov kev teb thiab kev ciaj sia tag nrho ntawm cov neeg mob uas muaj HER2-positive gastric adenocarcinoma (GC) lossis gastroesophageal junction (GEJ) adenocarcinoma. Qhov kev sim no tau sau npe rau 125 tus neeg mob uas tau kho nrog DS-8201, qhia txog tus nqi teb (ORR) ntawm 51%, lub sijhawm teb nruab nrab (DOR) ntawm 11.3 lub hlis, thiab tus nqi tswj kab mob (DCR) ntawm 86%.
Daim ntawv tshawb fawb theem III DESTINY-Gastric04 tau soj ntsuam qhov ua tau zoo thiab kev nyab xeeb ntawm Trastuzumab Deruxtecan (6.4 mg/kg) piv rau ramucirumab ntxiv rau paclitaxel ua kev kho mob thib ob rau cov neeg mob uas muaj HER2-positive tsis tuaj yeem phais thiab/lossis metastatic gastric lossis GEJ adenocarcinoma. Cov txiaj ntsig tau qhia tias, txij li Lub Kaum Hli 24, 2024, pawg trastuzumab deruxtecan tau ua pov thawj tias muaj kev ciaj sia ntev (OS) (14.7 lub hlis vs. 11.4 lub hlis, HR = 0.70, P = 0.0044) thiab kev ciaj sia tsis muaj kev nce qib (PFS) (6.7 lub hlis vs. 5.6 lub hlis). ORR kuj siab dua (44.3% vs. 29.1%), ib yam li DCR (91.9% vs. 75.9%).
Trastuzumab deruxtecan (yav tas los hu ua DS-8201), ib qho tshuaj antibody-drug conjugate uas muaj cov tshuaj humanized anti-HER2 monoclonal antibody txuas nrog rau topoisomerase I inhibitor payload los ntawm tetrapeptide-based cleavable linker, tau pom zoo rau kev kho mob ntawm cov neeg mob uas muaj mob qog noj ntshav mis HER2-positive metastatic. Tsis zoo li ntau lwm yam kev kho mob HER2-targeted uas tau pom zoo, trastuzumab deruxtecan kuj tseem tuaj yeem tsom mus rau cov hlwb qog uas qhia cov qib qis ntawm HER2 thiab tuaj yeem xa nws cov cytotoxic payload muaj zog (piv ntawm tshuaj rau antibody, 8: 1) los ntawm cov nyhuv bystander rau cov hlwb qog nyob sib ze uas qhia HER2 heterogeneously.
Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
Email：myimmnet@163.com
Lub sijhawm tshaj tawm: Lub Rau Hli-19-2025